Study to Evaluate Efficacy of LAI When Added to Multi-drug Regimen Compared to Multi-drug Regimen Alone
Status:
Completed
Trial end date:
2019-04-03
Target enrollment:
Participant gender:
Summary
A study to evaluate the effectiveness of Liposomal Amikacin for Inhalation (LAI) 590 mg
administered once daily (QD) when added to multi-drug regimen (MDR) in participants with
Nontuberculous Mycobacterial (NTM) lung infection caused by Mycobacterium Avium Complex (MAC)
that were refractory to treatment.
Participants were randomized 2:1 to LAI 590 mg administered QD + MDR or MDR alone.